PRCT - PROCEPT BioRobotics Corporation
PROCEPT BioRobotics offers Aquablation to help with symptom relief while preserving sexual and urinary functions for patients. PRCT has ongoing HYDROS placements that further expand its commercial potential. That should eventually require replacements and help equipment revenues. In that sense, PRCT's recurring sales with consumables could become increasingly valuable. However, that assumes that procedure growth continues as well.
On October 19, 2026, PROCEPT BioRobotics Corp (PRCT) shares rose 4.0% to a current price of $18.28. This price is within a 52-week range of $16.67 to $38.11, re
SAN JOSE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2026 after market close on Wednesday, November 4, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
SAN DIEGO, Oct. 1, 2026 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit has been filed concerning certain investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT). Investors who purchased shares of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) have certain options and should contact the Shareholders Foundation at [email protected] or +1 (858) 779-1554.
A lawsuit was filed for certain investors in PROCEPT BioRobotics Corporation shares. NASDAQ: PRCT investors should contact the Shareholders Foundation
Varex Imaging (NASDAQ: VREX - Get Free Report) and PROCEPT BioRobotics (NASDAQ: PRCT - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings. Valuation and Earnings This table compares Varex
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
New York, New York--(Newsfile Corp. - September 22, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation ("PROCEPT" or the "Company") (NASDAQ: PRCT) on behalf of all purchasers of PROCEPT common stock between February 28, 2024 and February 25, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in PROCEPT and have suffered losses, you may CLICK HERE to contact us.
LOS ANGELES, Sept. 22, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises PROCEPT BioRobotics Corporation, (“PROCEPT” or the "Company") (NASDAQ: PRCT) investors of a class action on behalf of investors that bought securities between February 28, 2024 and February 25, 2026, inclusive (the “Class Period”). PROCEPT investors have until September 22, 2026 to file a lead plaintiff motion.
NEW YORK, Sept. 22, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against PROCEPT BioRobotics Corporation ("Procept" or "the Company") (NASDAQ: PRCT ) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
New York, New York--(Newsfile Corp. - September 21, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation ("PROCEPT" or the "Company") (NASDAQ: PRCT) on behalf of all purchasers of PROCEPT common stock between February 28, 2024 and February 25, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in PROCEPT and have suffered losses, you may CLICK HERE to contact us.
NEW YORK, Sept. 21, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) between February 28, 2024 and February 25, 2026, inclusive (the "Class Period"), of the important September 22, 2026 lead plaintiff deadline.
LOS ANGELES, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming September 22, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired PROCEPT BioRobotics Corporation (“PROCEPT” or the “Company”) (NASDAQ: PRCT) securities between February 28, 2024 and February 25, 2026 inclusive (the “Class Period”).
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of common stock of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) between February 28, 2024 and February 25, 2026, inclusive (the “Class Period”). PROCEPT is a medical technology company.For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.The Allegations: Rosen Law Firm is Investigating the Allegat.
SAN FRANCISCO, Sept. 21, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) that a securities class action has been filed after repeated surprise unit handpiece sales underperformance and gradual revelations of excess customer inventory levels driven by repeated, late-quarter, bulk discounts.
NEW YORK, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation (“PROCEPT” or the “Company”) (NASDAQ: PRCT) on behalf of all purchasers of PROCEPT common stock between February 28, 2024 and February 25, 2026 (the “Class Period”).
LOS ANGELES, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against PROCEPT BioRobotics Corporation (“Procept” or “the Company”) (NASDAQ: PRCT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) against certain of its officers and directors for alleged breaches of fiduciary duty.
SAN FRANCISCO, Sept. 19, 2026 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP alerts investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) that a securities class action has been filed after repeated surprise unit handpiece sales underperformance and gradual revelations of excess customer inventory levels driven by repeated, late-quarter, bulk discounts.
NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) between February 28, 2024 and February 25, 2026, inclusive (the “Class Period”), of the important September 22, 2026 lead plaintiff deadline.